Concepedia

Semra Yörük

SY

Statistics

Publications

4

Citations

117

H-Index

4

Active since

2001

Affiliations

Institut Gustave Roussy(Current)

Sanofi (Turkey)

Sanofi (France)

Sarah Cannon

Institut Bergonié

Semra Yörük is an author at Institut Gustave Roussy specializing in medicine, clinical trial reports, and antibody-drug conjugates.

Publications per year

2001–2024

4

Publications

4

Nasopharyngeal carcinoma in childhood: long-term results of 32 patients

Ömer Uzel, Semra Yörük, İsmet Şahinler et al. · Radiotherapy and Oncology · 2001 · 45 citations

, , +14

Efficacy and safety of the antibody-drug conjugate (ADC) SAR408701 in patients (pts) with non-squamous non-small cell lung cancer (NSQ NSCLC) expressing carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5).

Anas Gazzah, Charles Ricordel, Sophie Cousin et al. · Journal of Clinical Oncology · 2020 · 38 citations

, , +17

OA08.05 Tusamitamab Ravtansine vs Docetaxel in Previously Treated Advanced Nonsquamous NSCLC: Results from Phase 3 CARMEN-LC03 Trial

B. Besse, Giuseppe Lo Russo, H. Léna et al. · Journal of Thoracic Oncology · 2024 · 23 citations · Full text

, , +3

Phase III trial comparing antibody-drug conjugate (ADC) SAR408701 with docetaxel in patients with metastatic non-squamous non-small cell lung cancer (NSQ NSCLC) failing chemotherapy and immunotherapy.

Melissa L. Johnson, Mustapha Chadjaa, Semra Yörük et al. · Journal of Clinical Oncology · 2020 · 11 citations

, , +17

1–4 of 4